GLP-1 receptor agonists × cardiac & vascular function

TrialJournal of the American College of Cardiology2024

Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.

Mark C Petrie et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 1,145 people · 2024

Randomised comparison

Raised cardiac & vascular function

+4.50points+0.80 to +8.20

As reported

difference 4.5 points, 95% CI 0.80–8.20

One number in the abstract

the abstract, start to end

(estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2;

← favours treatmentfavours comparator →
could be chance
Cardiac & vascular function
4.50.80–8.20
GLP-1 receptor agonistsCardiac & vascular function

GLP-1 receptor agonists × cardiac & vascular functionhelps?mixed

unlikelylikely
0.501.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

41 papers cite it

2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 38819334